UK markets closed
NIKKEI 225
38,703.51 +213.34 (+0.55%) HANG SENG
18,476.80 +51.84 (+0.28%) CRUDE OIL
75.67 +1.60 (+2.16%) GOLD FUTURES
2,395.20 +4.30 (+0.18%) DOW
38,886.17 +78.84 (+0.20%) Bitcoin GBP
55,317.04 -256.75 (-0.46%)
Newron Pharmaceuticals S.p.A. (NP5.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
At close: 05:35PM CEST
| Previous close | 10.38 |
| Open | 10.32 |
| Bid | 10.22 x N/A |
| Ask | 10.34 x N/A |
| Day's range | 10.20 - 10.32 |
| 52-week range | 4.20 - 12.00 |
| Volume | |
| Avg. volume | 7,302 |
| Market cap | 191.908M |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.91 |
| Earnings date | 19 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireNewron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City
MILAN & MORRISTOWN, N.J., June 05, 2024--Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City. New hope emerges for treatment-resistant schizophrenia.
Business WireNewron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
MILAN, May 13, 2024--Newron reports new data from pivotal study 008A for chronic schizophrenia patients revealing clinically significant efficacy benefits over time.
Business WireNewron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
© 2024 Yahoo. All rights reserved.